- Home
- NXGL vs CRIS Comparison
NXGL vs CRIS Comparison
Compare NXGL & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | CRIS |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 14.6M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NXGL | CRIS |
|---|---|---|
| Price | $1.83 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 84.4K | ★ 97.5K |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,666,000.00 | $11,650,000.00 |
| Revenue This Year | $46.60 | $2.72 |
| Revenue Next Year | $47.96 | $8.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.37 | 13.56 |
| 52 Week Low | $1.56 | $1.02 |
| 52 Week High | $5.10 | $4.64 |
Technical Indicators
Market Signals| Indicator | NXGL | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 38.42 | 52.90 |
| Support Level | $1.68 | $1.08 |
| Resistance Level | $2.56 | $1.21 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 26.50 | 100.00 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.